Virax Biolabs Group Statistics
Total Valuation
VRAX has a market cap or net worth of $1.63 million. The enterprise value is -$3.23 million.
| Market Cap | 1.63M |
| Enterprise Value | -3.23M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, before market open.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
VRAX has 2.36 million shares outstanding. The number of shares has increased by 664.03% in one year.
| Shares Outstanding | 2.36M |
| Shares Change (YoY) | +664.03% |
| Shares Change (QoQ) | +67.01% |
| Owned by Insiders (%) | 26.80% |
| Owned by Institutions (%) | 5.68% |
| Float | 1.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.44 |
| Forward PS | n/a |
| PB Ratio | 0.27 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.59, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.59 |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -432.43 |
Financial Efficiency
Return on equity (ROE) is -129.10% and return on invested capital (ROIC) is -107.42%.
| Return on Equity (ROE) | -129.10% |
| Return on Assets (ROA) | -112.40% |
| Return on Capital (ROIC) | -107.42% |
| Revenue Per Employee | $7,209 |
| Profits Per Employee | -$629,412 |
| Employee Count | 11 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 3.08 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.35% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -84.35% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 2.14 |
| Relative Strength Index (RSI) | 46.01 |
| Average Volume (30 Days) | 71,641 |
Short Selling Information
The latest short interest is 11,994, so 0.51% of the outstanding shares have been sold short.
| Short Interest | 11,994 |
| Short Previous Month | 2,959 |
| Short % of Shares Out | 0.51% |
| Short % of Float | 1.04% |
| Short Ratio (days to cover) | 0.47 |
Income Statement
In the last 12 months, VRAX had revenue of $79,301 and -$6.92 million in losses. Loss per share was -$2.94.
| Revenue | 79,301 |
| Gross Profit | 9,035 |
| Operating Income | -7.00M |
| Pretax Income | -6.92M |
| Net Income | -6.92M |
| EBITDA | n/a |
| EBIT | -6.91M |
| Loss Per Share | -$2.94 |
Balance Sheet
The company has $5.11 million in cash and $181,706 in debt, giving a net cash position of $4.93 million or $2.09 per share.
| Cash & Cash Equivalents | 5.11M |
| Total Debt | 181,706 |
| Net Cash | 4.93M |
| Net Cash Per Share | $2.09 |
| Equity / Book Value | 6.33M |
| Book Value Per Share | 2.68 |
| Working Capital | 5.18M |
Cash Flow
In the last 12 months, operating cash flow was -$5.34 million and capital expenditures -$708,181, giving a free cash flow of -$6.05 million.
| Operating Cash Flow | -5.34M |
| Capital Expenditures | -708,181 |
| Free Cash Flow | -6.05M |
| FCF Per Share | -$3.41 |
Margins
Gross margin is 11.39%, with operating and profit margins of -8,825.12% and -8,730.70%.
| Gross Margin | 11.39% |
| Operating Margin | -8,825.12% |
| Pretax Margin | -8,730.70% |
| Profit Margin | -8,730.70% |
| EBITDA Margin | n/a |
| EBIT Margin | -8,710.56% |
| FCF Margin | -7,628.04% |
Dividends & Yields
VRAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -664.03% |
| Shareholder Yield | -664.03% |
| Earnings Yield | -407.13% |
| FCF Yield | -355.71% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 18, 2023. It was a reverse split with a ratio of 1:10.
| Last Split Date | Dec 18, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
VRAX has an Altman Z-Score of -4.19 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.19 |
| Piotroski F-Score | 3 |